Sarah Noémie Dumont

Dr. Sarah Noémie Dumont


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2015 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
CRCatalina Ruiz-Mesa
Catalina Ruiz-Mesa
JGJohn M. Goldberg
John M. Goldberg
AMAlvaro J. Coronado Munoz
Alvaro J. Coronado Munoz
SDSarah Noémie Dumont
Sarah Noémie Dumont
Jonathan TrentJonathan Trent
Jonathan Trent

4 November 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
SASAMY AMMARI
SAMY AMMARI
RCRaoul Sallé de Chou
Raoul Sallé de Chou
CBCorinne Balleyguier
Corinne Balleyguier
ECEmilie Chouzenoux
Emilie Chouzenoux
MTMehdi Touat
Mehdi Touat
TATAREK Assi
TAREK Assi
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adult patients with a median survival of around one year. Prediction of survival outcomes in GBM patients could represent a huge step in treatment personalization. The objective of this study was to develop machine learning (ML) algorithms for survival prediction of GBM patient. We identified a radiomic signature on a training-set composed of data from the 2019 BraTS challenge (210 patients) from MRI retrieved at diagnosis. Then, using this signature along with the age of the patients for training classification models, we obtained on test-sets AUCs of 0.85, 0.74 and 0.58 (0.92, 0.88 and 0.75 on the training-sets) for survival at 9-, 12- and 15-months, respectively. This signature was then validated on an independent cohort of 116 GBM patients with confirmed disease relapse for the prediction of patients surviving less or more than the median OS of 22 months. Our model insured an AUC of 0.71 (0.65 on train). The Kaplan–Meier method showed significant OS difference between groups (log-rank p = 0.05). These results suggest that radiomic signatures may improve survival outcome predictions in GBM thus creating a solid clinical tool for tailoring therapy in this population.

16 April 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Bernd KasperBernd Kasper
Bernd Kasper
ELEstelle Lecointe-Artzner
Estelle Lecointe-Artzner
SWSuzanne Wait
Suzanne Wait
SBShannon Boldon
Shannon Boldon
RWRoger Wilson
Roger Wilson
MWMarkus Wartenberg
Markus Wartenberg
The Sarcoma Policy Checklist was created by a multidisciplinary expert group to provide policymakers with priority areas to improve care for sarcoma patients. This paper draws on this research, by looking more closely at how France, Germany, Italy, Spain, Sweden and the United Kingdom are addressing each of these priority areas. It aims to highlight key gaps in research, policy and practice, as well as ongoing initiatives that may impact the future care of sarcoma patients in different European countries. A pragmatic review of the published and web-based literature was undertaken. Telephone interviews were conducted in each country with clinical and patient experts to substantiate findings. Research findings were discussed within the expert group and developed into five core policy recommendations. The five identified priority areas were: the development of designated and accredited centres of reference; more professional training; multidisciplinary care; greater incentives for research and innovation; and more rapid access to effective treatments. Most of the countries studied have ongoing initiatives addressing many of these priorities; however, many are in early stages of development, or require additional funding and resources. Gaps in access to quality care are particularly concerning in many of Europe’s lower-resourced countries. Equitable access to information, clinical trials, innovative treatments and quality specialist care should be available to all sarcoma patients. Achieving this across Europe will require close collaboration between all stakeholders at both the national and European level.

14 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
SASAMY AMMARI
SAMY AMMARI
RCRaoul Sallé de Chou
Raoul Sallé de Chou
TATAREK Assi
TAREK Assi
MTMehdi Touat
Mehdi Touat
ECEmilie Chouzenoux
Emilie Chouzenoux
CSCristina Smolenschi
Cristina Smolenschi
Anti-angiogenic therapy with bevacizumab is a widely used therapeutic option for recurrent glioblastoma (GBM). Nevertheless, the therapeutic response remains highly heterogeneous among GBM patients with discordant outcomes. Recent data have shown that radiomics, an advanced recent imaging analysis method, can help to predict both prognosis and therapy in a multitude of solid tumours. The objective of this study was to identify novel biomarkers, extracted from MRI and clinical data, which could predict overall survival (OS) and progression-free survival (PFS) in GBM patients treated with bevacizumab using machine-learning algorithms. In a cohort of 194 recurrent GBM patients (age range 18–80), radiomics data from pre-treatment T2 FLAIR and gadolinium-injected MRI images along with clinical features were analysed. Binary classification models for OS at 9, 12, and 15 months were evaluated. Our classification models successfully stratified the OS. The AUCs were equal to 0.78, 0.85, and 0.76 on the test sets (0.79, 0.82, and 0.87 on the training sets) for the 9-, 12-, and 15-month endpoints, respectively. Regressions yielded a C-index of 0.64 (0.74) for OS and 0.57 (0.69) for PFS. These results suggest that radiomics could assist in the elaboration of a predictive model for treatment selection in recurrent GBM patients.

5 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Elise Nassif HaddadElise Nassif Haddad
Elise Nassif Haddad
EAEdouard Auclin
Edouard Auclin
RBRastilav Bahleda
Rastilav Bahleda
CHCharles Honoré
Charles Honoré
OMOlivier Mir
Olivier Mir
ADArmelle Dufresne
Armelle Dufresne
(1) Background: locally resected high-grade sarcomas relapse in 40% of cases. There is no prognostic or predictive genomic marker for response to peri-operative chemotherapy. (2) Methods: MOSCATO and ProfiLER are pan-tumor prospective precision medicine trials for advanced tumors. Molecular analysis in both trials comprised targeted next-generation sequencing and comparative genomic hybridization array. We investigated if molecular alterations identified in these trials in sarcomas were associated with disease-free survival (DFS) and response to anthracyclines. (3) Results: this analysis included 215 sarcomas, amongst which 53 leiomyosarcomas, 27 rhabdomyosarcomas, 20 undifferentiated pleomorphic sarcomas, and 17 liposarcomas. The most frequently altered gene was TP53 (46 mutations and eight deletions). There were 149 surgically resected localized sarcomas. Median DFS in TP53 wild type (WT), deleted, and mutated sarcomas was 16, 10, and 10 months, respectively (p = 0.028; deletions: HR = 1.55; 95% CI = 0.75–3.19; mutations: HR = 1.70; 95%CI = 1.13–2.64). In multivariate analysis, TP53 mutations remained associated with shorter DFS (p = 0.027; HR = 2.30; 95%CI = 1.10–4.82). There were 161 localized and advanced sarcomas evaluable for response to anthracyclines. Objective response rates were 35% and 55% in TP53 WT and mutated sarcomas, respectively (OR = 2.24; 95%CI = 1.01–5.03; p = 0.05). In multivariate analysis, TP53 mutations remained associated with increased response (OR = 3.24; 95%CI = 1.30–8.45; p = 0.01). (4) Conclusions: TP53 mutations are associated with shorter DFS and increased response to anthracyclines. Post-validation, these findings could assist in decision-making for peri-operative treatments.

22 February 2023 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
CSCristina Smolenschi
Cristina Smolenschi
ERElie Rassy
Elie Rassy
JPJohan Pallud
Johan Pallud
EDEdouard Dezamis
Edouard Dezamis
RCRazvan Copaciu
Razvan Copaciu
SDSarah Noémie Dumont
Sarah Noémie Dumont